FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1863 December 17, 1998 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Poulson, J.

To the Editor: In her perceptive Occasional Note (June 18 issue),¹ Dr. Poulson does not mention two of the most demeaning bitter pills that are common in oncology and that can influence how physicians treat patients with cancer.

It is common to refer to second-line treatment as "salvage," which gives the impression that doctors are rummaging through the junkyard of a patient's body looking for something that is still worth saving or poking through a flooded basement in the hope of finding something that is not beyond repair. The term "salvage treatment" is often used in descriptions of clinical trials . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.